The use of molecular volumetric parameters for the evaluation of Lu-177 PSMA I&T therapy response and survival
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Nuclear Medicine"
DOI: 10.1007/s12149-019-01376-3
Abstract: The primary aim of this study was to evaluate the volumetric therapy response via Ga-68 PSMA I&T PET/CT in patients treated with Lu-177 PSMA I&T therapy. The secondary purpose was to determine the impact of… read more here.
Keywords: response; therapy response; 177 psma; therapy ... See more keywords
Lutetium‐177 PSMA – the new snake oil? An Australian experience
Sign Up to like & getrecommendations! Published in 2025 at "BJU International"
DOI: 10.1111/bju.16731
Abstract: Metastatic castrate-resistant prostate cancer (mCRPC) demonstrates an aggressive disease course with limited systemic therapeutic options. It has a mean survival rate of between 9 and 36 months [1 read more here.
Keywords: snake oil; psma new; oil australian; 177 psma ... See more keywords
Prognostic role of early prostate specific antigen changes after [177 Lu]Lu-PSMA radioligand therapy of metastasized prostate cancer: A meta-analysis.
Sign Up to like & getrecommendations! Published in 2023 at "European journal of clinical investigation"
DOI: 10.1111/eci.14014
Abstract: BACKGROUND Approximately 10%-20% of prostate cancers progress to metastatic and castration-resistant forms (mCRPC). Radioligand (RLT) therapy with [177 Lu]Lu-prostate-specific membrane antigen (PSMA) is an emerging treatment for metastasized mCRPC and its efficacy is assessed not… read more here.
Keywords: 177 psma; prostate specific; prostate; therapy ... See more keywords
Visual deficit possibly caused by lutetium-177 PSMA treatment
Sign Up to like & getrecommendations! Published in 2018 at "BMJ Case Reports"
DOI: 10.1136/bcr-2018-225508
Abstract: This report describes a case of a 54-year-old man who underwent lutetium-177-PSMA therapy in the setting of metastatic castration-resistant prostate cancer (mCRPC) in the University Medical Center Utrecht. Following administration of the second cycle, patient… read more here.
Keywords: deficit possibly; 177 psma; lutetium 177; psma ... See more keywords
Update to a randomized controlled trial of lutetium-177-PSMA in Oligo-metastatic hormone-sensitive prostate cancer: the BULLSEYE trial
Sign Up to like & getrecommendations! Published in 2021 at "Trials"
DOI: 10.1186/s13063-021-05733-4
Abstract: Background The BULLSEYE trial is a multicenter, open-label, randomized controlled trial to test the hypothesis if 177 Lu-PSMA is an effective treatment in oligometastatic hormone-sensitive prostate cancer (oHSPC) to prolong the progression-free survival (PFS) and… read more here.
Keywords: trial; study; hormone sensitive; 177 psma ... See more keywords
Association of genomic alterations with clinical outcomes following lutetium-177-PSMA vipivotide tetraxetan in men with metastatic castrate-resistant prostate cancer.
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.16_suppl.5057
Abstract: 5057 Background: Lutetium-177-PSMA vipivotide tetraxetan (Lu177) is approved for men with PSMA-positive metastatic castrate-resistant prostate cancer (mCRPC) previously treated with androgen receptor signaling inhibitors and taxane chemotherapy. The tumor genomic alterations conferring sensitivity or resistance… read more here.
Keywords: cancer; prostate cancer; 177 psma; genomic alterations ... See more keywords
Survival and hospitalizations with lutetium (Lu)-177 vipivotide tetraxetan in veterans with underlying genomic alterations.
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2025.43.16_suppl.5068
Abstract: 5068 Background: Lutetium-Lu 177 vipivotide tetraxetan ( 177 Lu-PSMA-617) is a radioligand therapy used to treat metastatic castration resistant prostate cancer (mCRPC) with limited real-world survival data outside of large academic centers. Emerging data suggests… read more here.
Keywords: oncology; age; psma 617; 177 psma ... See more keywords
Association of baseline and on-treatment ctDNA fraction with clinical outcomes in patients with mCRPC in the PSMAfore study of 177 Lu-PSMA-617.
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2025.43.5_suppl.16
Abstract: 16 Background: In PSMAfore (NCT04689828), [ 177 Lu]Lu-PSMA-617 ( 177 Lu-PSMA-617) prolonged rPFS versus androgen receptor pathway inhibitor (ARPI) change in taxane-naive adults with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) progressing once on an ARPI.… read more here.
Keywords: baseline; psma 617; 177 psma; ctdna fraction ... See more keywords
Assessing the clinical impact of tumor volume on response to 177 Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer.
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2025.43.5_suppl.175
Abstract: 175 Background: 177 Lu-PSMA-617, a PSMA-directed radionuclide therapy, is an emerging treatment for metastatic castration-resistant prostate cancer (mCRPC). This retrospective study evaluates clinical outcomes of 177 Lu-PSMA-617 in low volume (LV) and high volume (HV)… read more here.
Keywords: months patients; therapy; 177 psma; psma ... See more keywords
Clinical protocols to monitor efficacy of [ 177 Lu]Lu-PSMA radiopharmaceutical therapy in metastatic castration-resistant prostate cancer.
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2025.43.5_suppl.39
Abstract: 39 Background: To assess the prognostic value of post-therapy [ 177 Lu]Lu-PSMA (LuPSMA)-SPECT/CT by visual RECIP 1.0 during LuPSMA radioligand therapy and to develop an evidence-based clinical protocol to monitor efficacy to LuPSMA. Methods: Patients… read more here.
Keywords: monitor efficacy; therapy; lupsma spect; 177 psma ... See more keywords